Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $43.25.
A number of research firms have weighed in on LYEL. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Lyell Immunopharma in a report on Wednesday. Citizens Jmp began coverage on Lyell Immunopharma in a report on Monday, March 9th. They set a “market outperform” rating and a $34.00 target price for the company. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Robert W. Baird set a $49.00 target price on Lyell Immunopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. Finally, Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th.
Read Our Latest Stock Analysis on Lyell Immunopharma
Lyell Immunopharma Stock Down 15.6%
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.10). The company had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%. Equities analysts expect that Lyell Immunopharma will post -8.37 earnings per share for the current year.
Hedge Funds Weigh In On Lyell Immunopharma
A number of large investors have recently made changes to their positions in the business. Bank of America Corp DE increased its position in shares of Lyell Immunopharma by 314.2% during the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock worth $668,000 after purchasing an additional 25,276 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Lyell Immunopharma by 194.8% during the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after purchasing an additional 76,921 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma during the first quarter worth $445,000. Dimensional Fund Advisors LP acquired a new position in shares of Lyell Immunopharma during the first quarter worth $959,000. Finally, Invesco Ltd. acquired a new position in shares of Lyell Immunopharma during the fourth quarter worth $3,036,000. 66.05% of the stock is owned by institutional investors and hedge funds.
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.
Featured Stories
- Five stocks we like better than Lyell Immunopharma
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
